Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Most of these companies have massive dilution. I’d take the IP here over any of the others in this OTC sector yet it has about the lowest valuation.
Somewhat. They all get painted with the same brush and MM’s manipulating the price. I think some of it also has to do with Emerald taking it over and having a dispute with one of their subsidiaries and blowing through a lot of cash with that entity.
I’ve always believed EMBI has the goods. Probably more than anyone in the sector including GWPH. It all comes down to funding into Phase 2 trials. I think Murphy is very confident in what they have or he wouldn’t stick around. Never been any insider selling from what I’ve seen and never pumped nor will it be. They move slower than I’d like. I think the price should be around .50-$1 using others in the sector as a comparison and based on their IP.
Right now it’s an eye drop and it looks like their formulation works with a once a day application. I’ve seen the argument that gels might be better but it all will probably be moot as implants in the eye to administer drugs will be what everyone will use soon. Here’s an article that came out today from the university.
https://news.olemiss.edu/um-partners-emerald-bioscience-license-cannabis-derived-drugs/
That’s kind of how I see it. EMBI has legit IP and Brian Murphy is solid. We’ll see if they can execute with the necessary financing.
I’m waiting for the pump here too.
Hope so but patents haven’t given EMBI a boost.
I’ve owned this and EMBI for a few years. EMBI seems to be a couple years ahead of InMed with glaucoma and their market cap is lower. It doesn’t seem like either of these companies will move much until they get into trials.
Yep. This should be sitting at .30 while waiting on news.
Is anyone willing to share their opinion on if today is the day to get in or Thursday? Specifically, will there be profit taking after the 1st of the year dropping the price? Thank you.
There’s no good reason to do a reverse split at these levels. This could easily run up to a $1 on news and that kind of jump wouldn’t happen if they’re listed on Nasdaq. There probably won’t be much news until the 2nd quarter. EMBI has the IP so they’re more legit than anyone not named GW or Zyne. It all comes down to being able to execute. Murphy is key to advancing this and of course continuing to raise money to get the first trials done which I expect.
It’s completely legitimate. I think they have better IP than anyone in the sector long term. It comes down to if they can execute.
Where are you finding what previous insider is selling? Thank you.
Emerald/Nemus has been working with Teewinot for over 2 years using their biosynthesis technology. Nemus starts clinical trials in 5 months for their glaucoma drug. They might be ahead of everyone.
Yeah this price is a mystery. Insiders sell every month and it sticks around $4. If I owned it I’d dump a little each day until I was out. It’s probably worth 20 cents per share based on other companies in the sector.
In what way?
That’s a rarely used satellite office. All of their work is done at the university and at their collaborators locations.
Sessions has no impact on Nemus and never has. No idea what this is. Long overdue.
Still here. Hang on to this gentlemen. They have money and this is the jewel of Emerald. I'm happy they shifted their focus back to glaucoma. They know it works.
Lol. Murphy doesn't own anything but stock.
This is the last time I'll respond to you since your butthurt is too hard to read. The Schneider deal seems to be a real misstep but I'll reserve full judgement to when all the facts come out. I assume they won't get a penny but the law firm taking it on contingency must think otherwise. They're not doing Nemus a favor.
If you consider someone with Lykos' pedigree devoting the majority of his time to this at $20k/mo enriching himself then that must seem like a lot of money to you. The guy has raised $12 million in 3 years which is more than anyone else OTC in this sector. Most are probably associates so you think he's going to screw them over for a salary he could get just waking up in the morning?
No idea how involved Ingram is but he's still comfortable enough to be on the board and he did put in $250k.
You have no understanding of the loan repayment .
Still haven't heard your explanation of how the shell guys are relevant. Don't need to either.
Nobody has lost money yet unless they sold and I certainly don't think that highly of myself that I could influence people to buy or sell nor would I want to.
Are you suggesting that they're late on their 10Q and everyone else has theirs out already?
That's fine but what does that have to do with Nemus other than they were the officers of the shell? They had no connection to Nemus before the merger and have had no connection since other then they were paid 3 million shares for the shell and they dumped. Tell us why this should concern us. Maybe I'm stupid but I'm missing the correlation that the shell guys are scummy and Nemus.
He seems like a sharp guy and everyone has a right to be critical of execution but when it comes to allegations of impropriety, I'm going to say something. It didn't happen.
I have no idea what you're alleging. If you think one penny from the shell officers dumping made it into anyone in Nemus' pocket past or present then you're nuts. There's a whole industry where shells are used for companies to go public cheaply and the previous officers cash in. It's big money and the SEC has allowed it for now. If you want to argue that they shouldn't have gone that route I might agree but you must be trolling if you think anyone other than the shell guys got anything on the deal. Is that your theory?
Thanks counselor. I wonder why it's being taken on contingency?
It looks like the local guy might be personally liable and if a firm this size took it on contingency, they think they're going to win and they know there's significant assets within reach.
Nemus took over a shell company and Mendez was one of the officers of the shell trucking company. Are you surprised the officers from the shell dumped? Do you think anyone from Nemus had ever heard of these guys before the deal? What's your point?
Berecz could make her salary anywhere and Murphy could make more doing just about anything else with his background. How much money are you alleging current and former management has cashed in?
I won't argue that as it relates to the stock price and perhaps they could be further along from the outside looking in but they have done more to create value with patents and research than anyone else and raised more money than anyone else not on a major exchange. And nobody in management is dirty. It's high risk. Take it or leave it.
if you want to be critical of execution that's one thing but if you choose to be cryptic and insinuate that management is operating like any other penny stock and using this as a piggy bank then you should move on as nothing could be further from the truth. All of them could be doing other things that are much more lucrative and more rewarding than chasing money. They must believe in it.
Too cryptic for me. Sounds like you've soured on it and should sell. One thing I know for sure is management is ethically above reproach and nobody has enriched themselves. Their execution up to this point is subject to debate.
Agreed. They probably lost 4-5 months on the Schneider deal. If they hadn't raised the $2 million I'd be very concerned. I look at it that they raised it when they had no leverage, the relationship with the university seems to be solid and Lykos has devoted 3 years to this with no salary per their disclosures, no insider sales and Murphy has done this before.
No idea who did the deal. You don't think Lykos has a right to continue to work on something else while he works with Nemus? It's not like he has to devote much time to it. It's a business he knows and all it takes is capital and hiring good people. It's not a restaurant.
I was shocked they annnoucned they raised $20 million figuring they'd do the small raises until they got further down the road. They've been able to do that whenever they've needed it so there's no indication that won't continue as they move forward. The $20 million is disappointing but this is far from dead. I'm concerned about what went down but I reserve judgment until the facts come out. Raising the $2 million under crunch time gives them a longer leash with me. It's a high risk venture and even with good management who does things by the book, bad things can happen.
It's a bit dramatic to say the company is dead. If they weren't able to raise a years worth of capital then you might be right but they did and that was after the $20 million debacle. I'm sure we'll eventually find out what happened but if one were to guess, they must have relied heavily on the local group connected to Schneider in moving forward on the deal and maybe those local people are liable as well. If the litigation moves forward then that would indicate there's money to recover because they're not going to pay attorneys if there aren't funds to recover.
The stock price is very frustrating but the other penny stocks in the sector have higher valuations mostly because they're pumping away. They're not ahead of Nemus in drug development. InMed has probably spent $200k pumping their biosynthesis story for a year like they're the only ones doing it and I think there's been some insider selling lately. Nemus should now have enough money to get into Phase II for their leading drug candidate that seems to have a high probability of being approved. Hardly a dead company.
Zynerba has been around longer in another entity and the CEO was a fairly big name. They've had their issues and that stock got up to $40 immediately so most everyone is upside down right now.
One can make the argument about having a higher profile but they've raised the money when they've needed to and it isn't easy with a penny stock.
Nobody has really come up with an effective cannabinoid drug that meets FDA standards so it's very risky until someone does. Nemus should have enough money now to get into Phase II and if they have positive results, the share price will move up and the pool of potential investors will as well. It's hard to raise big money with an OTC company and especially in this sector.
You're just not going to get this group to pump the stock like all the others do InMed is spending quite a bit on promotion. I can see the argument for it as it relates to share price but it's a bit slimy. All you're going to get here are press releases and no leaks.
No idea where the other link came from. Here's the right one.
https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm583295.htm
Here's an example of what's to come. If FDA approved drugs hit the market, I think it will go even further with shut downs and seizures when there's big money on the line.
https://www.jihadwatch.org/2017/10/us-antifa-and-other-leftist-groups-met-in-germany-with-al-qaeda-and-isis-to-plot-trumps-destruction
I think everyone is unhappy with the Schneider deal. The vetting process seemed to be nonexistent at face value. I also think management should be much more communicative with shareholders. I think they're too by the book. Maybe there's even some arrogance there with the past successes they've all had. However, I do know that they're devoting all their time and effort to make this work. We don't know the whole story but one thing is for sure, none of these guys did anything nefarious. They may have used poor judgment but we really don't know what happened. One would think that the law firm has checked to see if there are recoverable assets. Perhaps there is personal liability with Schneider principals. I'm sure Nemus will be able to raise short term financing to move this thing along even if they don't recover anything from Scheider. If the litigation continues to move forward, I think that will mean they'll get a settlement without having to sue.
Anyway, it's easy to go after the Nemus group for things not working out so far. You see the vulture lawyers file class action suits when FDA trials don't work out or for any reason they can find but it only enriches them. As miffed as I am at what transpired, I'm hanging tough knowing this was always high risk. Good luck to everyone.
I don't know enough about Sabby. I might be way off base but I don't think management would take money from anyone they thought would hurt them.
No idea on Schneider. I don't know if no news means they're working on another raise or they have to be silent while they finalize the deal. I don't think anyone is panicking.
It's insane that the states have been allowed to let it go this far with no Federal scrutiny. There is no other drug I can think of that has been given this kind of leeway. There are no studies to support the benefits of what's being sold and no studies on the risks and side effects. It's complete lawlessness and we all know the majority is for recreational purposes.
This might be the first chip at the stone but once Pharma has drugs to protect, there's going to be a war. If the drugs are effective, I dont see how medical marijuana survives. Pharma will be much cheaper, safer and doctors will only prescribe approved drugs. It will be a tough fight becasue so much money and infrastructure has been poured into mm but they won't have a leg to stand on if there are effective FDA approved drugs.